The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system

Keyphrases

• Endothelin System 100%
• Sunitinib 100%
• Vascular Endothelial Growth Factor Receptor Inhibitor 100%
• Preeclampsia-like Syndrome 100%
• Blood Pressure 40%
• Preeclampsia 30%
• Proteinuria 30%
• Oxidative Stress 30%
• Endothelin 1 (ET-1) 30%
• Induced Hypertension 20%
• Histological Abnormalities 20%
• Renal Toxicity 20%
• Hypertension 10%
• Adverse Effects 10%
• Serum Creatinine 10%
• Histopathological Features 10%
• Urinary Excretion 10%
• Endothelin Receptor Antagonist 10%
• Tumor Subtype 10%
• Nitrate 10%
• Increased Blood Pressure 10%
• Nitric Oxide Metabolites 10%
• Angiogenesis Inhibitors 10%
• Nitric Oxide Bioavailability 10%
• Superoxide Dismutase Mimetic 10%
• Glomerular Endotheliosis 10%
• Renal Histology 10%
• Tempol 10%
• Macitentan 10%
• System Stress 10%
• Metabolite Excretion 10%
• Electron Microscopic Study 10%
• Renal Dysfunction 10%
• Multi-targeted Tyrosine Kinase Inhibitor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Syndrome 100%
• Preeclampsia 100%
• Endothelin 100%
• Sunitinib 100%
• Vasculotropin Receptor 100%
• Rat 40%
• Endothelin 1 30%
• Proteinuria 30%
• Hypertension 30%
• Nitric Oxide 20%
• Nephrotoxicity 20%
• Creatinine 10%
• Neoplasm 10%
• Bioavailability 10%
• Endothelin Receptor Antagonist 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Elevated Blood Pressure 10%
• Superoxide Dismutase 10%
• Macitentan 10%
• Nitric Acid Derivative 10%
• Tempol 10%
• Adverse Effect 10%